Form D · Pharmaceuticals

AVICANNA INC.

Toronto, A6 · CIK 0001811059

Offering snapshot reported Oct 24, 2022 · SEC filing

Reported sold
$2.04M
Offering amount: $2.04M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 17, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 24, 2022Initial$2,039,427No comparison5SEC filing
Jun 27, 2022Initial$1,099,939No comparison4SEC filing
Jun 23, 2022Initial$78,811No comparison6SEC filing
Mar 19, 2021Initial$4,511,724No comparison2SEC filing
Sep 3, 2020Initial$2,089,079No comparison51SEC filing
May 1, 2020Initial$185,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-462574

Source: Form D, filed Oct 24, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Amza Ali Executive
Aras Azadian Director, Executive
Giancarlo Davila Char Director
Janet Gieesselman Director
Dr. Assad Kazeminy Director
Benjamin Leavenworth Director
Eileen Mc Cormack Director
John Mc Vicar Director
Lucas Nosiglia Executive
Chandrakant Panchal Director
Dr. Chandrakant Panchal Director
Setu Purohit Director, Executive
Davender Sohi Executive
Dave Sohi Executive
David Allan White Director
Flavio Zaclis Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
480 University Avenue Suite 1502
Toronto, A6, M5G 1V2